Can you take Efavirenz with Myrac?

Efavirenz has a moderate potential interaction with Alcoholism.

During clinical trials, efavirenz was associated with an increase in the occurrence of serious psychiatric events, including severe depression, suicidal ideation, nonfatal suicide attempts, aggressive behavior, paranoid reactions, and manic reactions. Other factors associated with an increased occurrence of these psychiatric symptoms were history of injectable drug use, psychiatric history, or use of psychiatric medications at study entry; similar associations were observed in the efavirenz and control groups. Therapy with efavirenz should be administered cautiously in patients with current/history of psychiatric illness, emotional instability, or substance abuse. Patients with serious psychiatric adverse reactions should receive prompt medical evaluation to assess the possibility that symptoms are related to efavirenz use, and if so, to determine whether the risks of continued therapy outweigh the benefits.

Efavirenz has a moderate potential interaction with Depression.

During clinical trials, efavirenz was associated with an increase in the occurrence of serious psychiatric events, including severe depression, suicidal ideation, nonfatal suicide attempts, aggressive behavior, paranoid reactions, and manic reactions. Other factors associated with an increased occurrence of these psychiatric symptoms were history of injectable drug use, psychiatric history, or use of psychiatric medications at study entry; similar associations were observed in the efavirenz and control groups. Therapy with efavirenz should be administered cautiously in patients with current/history of psychiatric illness, emotional instability, or substance abuse. Patients with serious psychiatric adverse reactions should receive prompt medical evaluation to assess the possibility that symptoms are related to efavirenz use, and if so, to determine whether the risks of continued therapy outweigh the benefits.

Efavirenz has a moderate potential interaction with Drug Dependence.

During clinical trials, efavirenz was associated with an increase in the occurrence of serious psychiatric events, including severe depression, suicidal ideation, nonfatal suicide attempts, aggressive behavior, paranoid reactions, and manic reactions. Other factors associated with an increased occurrence of these psychiatric symptoms were history of injectable drug use, psychiatric history, or use of psychiatric medications at study entry; similar associations were observed in the efavirenz and control groups. Therapy with efavirenz should be administered cautiously in patients with current/history of psychiatric illness, emotional instability, or substance abuse. Patients with serious psychiatric adverse reactions should receive prompt medical evaluation to assess the possibility that symptoms are related to efavirenz use, and if so, to determine whether the risks of continued therapy outweigh the benefits.

The minocycline in Myrac has a moderate potential interaction with Esophageal Obstruction.

The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime. Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia. If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.

Efavirenz has a moderate potential interaction with Liver Disease.

Efavirenz is not recommended for patients with moderate or severe liver dysfunction; insufficient data are available to determine whether dose adjustment is needed. Patients with mild liver dysfunction may receive efavirenz without dose adjustment. Due to extensive CYP450-mediated metabolism and limited clinical experience in patients with liver dysfunction, therapy with efavirenz should be administered cautiously in patients with mild liver dysfunction; careful monitoring is recommended for these patients. In addition, postmarketing cases of hepatitis (including fulminant hepatitis progressing to liver failure requiring transplantation or resulting in death) have occurred during therapy with efavirenz; reports have included patients with underlying liver disease (including coinfection with hepatitis B or C). Monitoring of liver enzymes before and during therapy is recommended for all patients.

The minocycline in Myrac has a moderate potential interaction with Liver Disease.

The use of tetracyclines has rarely been associated with hepatotoxicity. Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs. Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction. Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling. Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.

Efavirenz has a moderate potential interaction with Long QT Syndrome.

QTc prolongation has been observed with the use of efavirenz. Alternatives to efavirenz should be considered when administered to patients at higher risk of torsade de pointes or when coadministered with a medication with known risk of torsade de pointes.

The minocycline in Myrac has a major potential interaction with Noninfectious Colitis.

Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis. The most common culprits include clindamycin and lincomycin. Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development. Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea after antibacterial use. Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary. Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity. Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.

Efavirenz has a moderate potential interaction with Psychiatric Disorders.

During clinical trials, efavirenz was associated with an increase in the occurrence of serious psychiatric events, including severe depression, suicidal ideation, nonfatal suicide attempts, aggressive behavior, paranoid reactions, and manic reactions. Other factors associated with an increased occurrence of these psychiatric symptoms were history of injectable drug use, psychiatric history, or use of psychiatric medications at study entry; similar associations were observed in the efavirenz and control groups. Therapy with efavirenz should be administered cautiously in patients with current/history of psychiatric illness, emotional instability, or substance abuse. Patients with serious psychiatric adverse reactions should receive prompt medical evaluation to assess the possibility that symptoms are related to efavirenz use, and if so, to determine whether the risks of continued therapy outweigh the benefits.

Efavirenz has a moderate potential interaction with Psychosis.

During clinical trials, efavirenz was associated with an increase in the occurrence of serious psychiatric events, including severe depression, suicidal ideation, nonfatal suicide attempts, aggressive behavior, paranoid reactions, and manic reactions. Other factors associated with an increased occurrence of these psychiatric symptoms were history of injectable drug use, psychiatric history, or use of psychiatric medications at study entry; similar associations were observed in the efavirenz and control groups. Therapy with efavirenz should be administered cautiously in patients with current/history of psychiatric illness, emotional instability, or substance abuse. Patients with serious psychiatric adverse reactions should receive prompt medical evaluation to assess the possibility that symptoms are related to efavirenz use, and if so, to determine whether the risks of continued therapy outweigh the benefits.

The minocycline in Myrac has a moderate potential interaction with Renal Dysfunction.

Tetracyclines (except doxycycline) are eliminated by the kidney to various extent. Patients with renal impairment may be at greater risk for tetracycline-associated hepatic and/or renal toxicity (increased BUN with consequent azotemia, hyperphosphatemia, and acidosis) due to decreased drug clearance. Therapy with tetracyclines should be administered cautiously at reduced dosages in patients with renal impairment. Clinical monitoring of renal and liver function is recommended, and serum tetracycline levels may be necessary during prolonged therapy.

Efavirenz has a moderate potential interaction with Seizures.

Convulsions have been observed in adult and pediatric patients receiving efavirenz, generally in the presence of known medical history of seizures. Caution should be taken with any patient with history of seizures. Anticonvulsant medications primarily metabolized by the liver (e.g., phenytoin, phenobarbital) may require periodic monitoring of plasma levels.